Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 15.01% is 137% above its 3-year average of 6.32%, near the high end of its 3-year range (2.61%–15.01%).
As of the fiscal period ended Tuesday, June 30, 2026. 73.25% above its 12-month average of 8.66%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 15.01%.
DEBT TO ASSETS RATIO
15.01%
DEBT TO ASSETS RATIO AVG TTM
8.66%
DEBT TO ASSETS RATIO AVG 3Y
6.32%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+73.25%
CURRENT VS 3Y AVG
+137.42%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 595 covered companies
CURRENT VS SECTOR MEDIAN
+14911.17%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$376.93M
Debt to Assets Ratio
15.01%
TTM Avg
8.66%
3Y Avg
6.32%
5Y Avg
N/A
Market Cap
$377.28M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$371.12M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$384.04M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$354.49M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$352.03M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$350.08M
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $376.93M | 15.01% | 8.66% | 6.32% | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $377.28M | 0.10% | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $371.12M | 0.25% | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $384.04M | 0.01% | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.49M | 0.00% | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $352.12M | 1.19% | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.03M | 0.19% | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $402.01M | 0.03% | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $350.08M | 0.38% | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.54M | 0.00% | N/A | N/A | N/A |
Debt/Assets
15.0%
Debt/Equity
0.20
Current Ratio
9.06
Interest Coverage
-347.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 15.01% |
| 2026-03-31 | 13.13% |
| 2025-12-31 | 9.88% |
| 2025-09-30 | 2.68% |
| 2025-06-30 | 2.61% |
| 2025-03-31 | 2.66% |
| 2024-12-31 | 2.71% |
| 2024-09-30 | 2.69% |
| 2024-06-30 | 2.75% |
| 2024-03-31 | 2.78% |
| 2023-12-31 | 12.07% |
| 2023-09-30 | 10.42% |
| 2023-06-30 | 2.78% |
